Neovascular Age-Related Macular Degeneration (nAMD)

Ophthalmology·MeSH: Macular Degeneration

Prevalence

2000.0 / 100K

Incidence

200.0 / 100K/yr

10 drugs in development·6 companies·7 clinical trials

Drug Pipeline by Phase

Compare drugs

150 ivt vs 4D-150 IVT150 ivt vs eylea150 ivt vs Ixo-vec (formerly ADVM-022)

Frequently asked questions

How many drugs are in development for Neovascular Age-Related Macular Degeneration (nAMD)?

BioSniper tracks 10 drugs in development for Neovascular Age-Related Macular Degeneration (nAMD) across 6 companies.

How many clinical trials target Neovascular Age-Related Macular Degeneration (nAMD)?

There are 7 clinical trials targeting Neovascular Age-Related Macular Degeneration (nAMD) tracked by BioSniper.

What is the prevalence of Neovascular Age-Related Macular Degeneration (nAMD)?

The estimated prevalence of Neovascular Age-Related Macular Degeneration (nAMD) is approximately 2000.0 per 100,000 population.

Deep-dive into Neovascular Age-Related Macular Degeneration (nAMD)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Neovascular Age-Related Macular Degeneration (nAMD) — Drugs in Development & Clinical Trials | BioSniper